Met Life Investment Management, LLC Kodiak Sciences Inc. Transaction History

Met Life Investment Management, LLC

  • $17.1 Billion
  • Q3 2024

Shares

35 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024
BUY
$3.01 - $7.45 $31,201 - $77,226
10,366 New
10,366 $54,000
Q2 2023

Apr 29, 2024
BUY
$4.3 - $9.48 $78,006 - $171,976
18,141 New
18,141 $125,000
Q1 2023

May 09, 2024
BUY
$4.81 - $8.88 $87,258 - $161,092
18,141 New
18,141 $112 Million
Q1 2022

May 10, 2024
BUY
$7.09 - $89.45 $128,619 - $1.62 Million
18,141 New
18,141 $140,000
Q1 2022

Mar 22, 2023
BUY
$7.09 - $89.45 $45,943 - $579,636
6,480 Added 55.57%
18,141 $140,000
Q1 2022

May 12, 2022
BUY
$7.09 - $89.45 $45,943 - $579,636
6,480 Added 55.57%
18,141 $140,000
Q4 2021

Jun 21, 2023
SELL
$80.85 - $128.49 $523,907 - $832,615
-6,480 Reduced 35.72%
11,661 $988,000
Q3 2021

May 17, 2024
SELL
$81.97 - $106.94 $75,740 - $98,812
-924 Reduced 7.34%
11,661 $1.12 Million
Q3 2021

Jun 21, 2023
SELL
$81.97 - $106.94 $531,165 - $692,971
-6,480 Reduced 35.72%
11,661 $1.12 Million
Q3 2021

Mar 22, 2023
SELL
$81.97 - $106.94 $75,740 - $98,812
-924 Reduced 7.34%
11,661 $1.12 Million
Q3 2021

Nov 15, 2021
SELL
$81.97 - $106.94 $75,740 - $98,812
-924 Reduced 7.34%
11,661 $1.12 Million
Q2 2021

Jun 21, 2023
SELL
$77.2 - $126.54 $428,923 - $703,056
-5,556 Reduced 30.63%
12,585 $1.17 Million
Q1 2021

May 17, 2024
BUY
$110.45 - $164.47 $245,088 - $364,958
2,219 Added 21.41%
12,585 $1.43 Million
Q1 2021

Jun 26, 2023
SELL
$110.45 - $164.47 $613,660 - $913,795
-5,556 Reduced 30.63%
12,585 $1.43 Billion
Q1 2021

Mar 22, 2023
SELL
$110.45 - $164.47 $83,279 - $124,010
-754 Reduced 5.65%
12,585 $1.43 Million
Q1 2021

May 14, 2021
SELL
$110.45 - $164.47 $83,279 - $124,010
-754 Reduced 5.65%
12,585 $1.43 Million
Q4 2020

May 24, 2024
BUY
$60.78 - $154.03 $27,168 - $68,851
447 Added 3.47%
13,339 $1.96 Million
Q4 2020

Jun 22, 2023
SELL
$60.78 - $154.03 $291,865 - $739,652
-4,802 Reduced 26.47%
13,339 $1.96 Million
Q4 2020

Mar 22, 2023
BUY
$60.78 - $154.03 $27,168 - $68,851
447 Added 3.47%
13,339 $1.96 Million
Q4 2020

Feb 16, 2021
BUY
$60.78 - $154.03 $27,168 - $68,851
447 Added 3.47%
13,339 $1.96 Million
Q3 2020

Jun 26, 2023
SELL
$45.05 - $59.27 $236,467 - $311,108
-5,249 Reduced 28.93%
12,892 $763,000
Q2 2020

May 24, 2024
BUY
$42.74 - $66.25 $107,961 - $167,347
2,526 Added 24.37%
12,892 $698 Million
Q2 2020

Jun 26, 2023
SELL
$42.74 - $66.25 $224,342 - $347,746
-5,249 Reduced 28.93%
12,892 $697,000
Q2 2020

Mar 22, 2023
BUY
$42.74 - $66.25 $33,978 - $52,668
795 Added 6.57%
12,892 $697,000
Q2 2020

Aug 14, 2020
BUY
$42.74 - $66.25 $33,978 - $52,668
795 Added 6.57%
12,892 $698,000
Q1 2020

Jul 12, 2023
SELL
$38.18 - $73.95 $230,759 - $446,953
-6,044 Reduced 33.32%
12,097 $577,000
Q1 2020

Mar 22, 2023
BUY
$38.18 - $73.95 $66,891 - $129,560
1,752 Added 16.94%
12,097 $577,000
Q1 2020

May 15, 2020
BUY
$38.18 - $73.95 $66,891 - $129,560
1,752 Added 16.94%
12,097 $577,000
Q4 2019

Jul 12, 2023
SELL
$13.9 - $76.65 $108,364 - $597,563
-7,796 Reduced 42.97%
10,345 $744,000
Q4 2019

Mar 22, 2023
SELL
$13.9 - $76.65 $31,177 - $171,925
-2,243 Reduced 17.82%
10,345 $744,000
Q4 2019

Feb 14, 2020
SELL
$13.9 - $76.65 $31,177 - $171,925
-2,243 Reduced 17.82%
10,345 $744,000
Q3 2019

Jul 12, 2023
SELL
$10.24 - $17.57 $56,862 - $97,566
-5,553 Reduced 30.61%
12,588 $181,000
Q3 2019

Mar 22, 2023
SELL
$10.24 - $17.57 $56,862 - $97,566
-5,553 Reduced 30.61%
12,588 $181,000
Q3 2019

Nov 14, 2019
BUY
$10.24 - $17.57 $128,901 - $221,171
12,588 New
12,588 $181,000
Q2 2019

Jul 12, 2023
SELL
$6.2 - $12.0 $34,428 - $66,636
-5,553 Reduced 30.61%
12,588 $147 Million

Others Institutions Holding KOD

# of Institutions
98
Shares Held
39M
Call Options Held
6.5K
Put Options Held
5.8K
View Full List

About Kodiak Sciences Inc.

KOD Quotes by TradingView
  • Ticker KOD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,040,200
  • Market Cap $455M
  • Description
  • Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...
More about KOD
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email